ImmunoGen, Inc. Announces Presentations at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
02 November 2010 - 9:30PM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a
biotechnology company that develops targeted antibody-based
anticancer products using its antibody expertise and Targeted
Antibody Payload (TAP) technology, today announced that several
ImmunoGen poster presentations will be made at the 22nd
EORTC-NCI-AACR Symposium on Molecular Targets and Cancer
Therapeutics to be held in Berlin, Germany, November 16-19,
2010.
“Our presentations at this Symposium reflect our expanding
product pipeline and technology portfolio,” commented John Lambert,
Ph.D., Executive Vice President and Chief Scientific Officer.
“We’ll be reporting additional clinical data for our IMGN388
compound as well as preclinical data generated in our development
of IMGN853, a TAP compound that targets Folate Receptor 1. We’ll
also be presenting data on one of our linkers that enhances the
effectiveness of TAP compounds against cancers with multi-drug
resistance.”
On Nov. 17 from 12-2:20 pm CET/6:00-8:20 am ET:
- “Antibody-maytansinoid conjugates
targeting Folate Receptor 1 for cancer therapy” (Abstract #236,
Poster board #193).
- “Negatively-charged sulfonate group in
linker improves potency of antibody-maytansinoid conjugates against
multidrug-resistant cancer cells” (Abstract #235, Poster board
#192).
On Nov. 19 from 8-9:30 am CET/2:00-3:30 am ET:
- “A Phase I Study of IMGN388, an
antibody drug conjugate targeting av Integrin, in patients with
solid tumors” (Abstract #472, Poster board #008).
Data on TAP compounds in development by ImmunoGen partners also
will be presented at this conference.
About the Topics of the Presentations
ImmunoGen develops targeted anticancer compounds using its TAP
technology and also conducts research to continue to expand the
utility of this technology. A TAP compound consists of a
tumor-targeting antibody with one of the Company’s proprietary
cancer-cell killing agents attached using an engineered ImmunoGen
linker. The antibody serves to target the TAP compound specifically
to cancer cells, and the cell-killing agent serves to kill these
cells. The linker controls the release and activation of the
cell-killing agent inside the cancer cell.
IMGN388 and IMGN853 are TAP compounds in development by
ImmunoGen. IMGN388 targets αv integrin and is in Phase I testing
for the treatment of solid tumors. IMGN853 targets the Folate
Receptor 1 found on ovarian cancer and other epithelial
malignancies. It is in preclinical testing. The linker being
discussed is an example of the technology created by the Company to
enable the development of highly effective TAP compounds for
cancers with multi-drug resistance.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using
the Company's expertise in tumor biology, monoclonal antibodies and
potent cancer-cell killing agents. The Company's TAP technology
uses monoclonal antibodies to deliver one of ImmunoGen's
proprietary cancer-cell killing agents specifically to tumor cells.
There are currently seven TAP compounds in the clinic, with a
wealth of clinical data reported with the technology. ImmunoGen’s
collaborative partners include Amgen, Bayer Schering Pharma, Biogen
Idec, Biotest, Genentech (a member of the Roche Group), Novartis,
and sanofi-aventis. The most advanced compound using ImmunoGen's
TAP technology, trastuzumab-DM1 (T-DM1), is in Phase III testing
through the Company's collaboration with Genentech. More
information about ImmunoGen can be found at www.immunogen.com.
This press release includes forward-looking
statements. For these statements, ImmunoGen claims the protection
of the safe harbor for forward-looking statements provided by the
Private Securities Litigation Reform Act of 1995. It should be
noted that there are risks and uncertainties related to the
development of novel anticancer products, including IMGN388 and
IMGN853, that include risks related to uncertainties around
preclinical and clinical studies conducted and their results. A
review of these risks can be found in ImmunoGen’s Annual Report on
Form 10-K for the fiscal year ended June 30, 2010 and other reports
filed with the Securities and Exchange Commission.
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jul 2023 to Jul 2024
